EU conditional marketing authorisation (CMA)

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.

What a conditional marketing authorisation is

EMA can grant a conditional marketing authorisation for medicines that address unmet medical needs on less comprehensive clinical data than normally required, where the benefit of immediate availability outweighs the risk that more data are still needed. Eligible medicines treat, prevent or diagnose seriously debilitating or life-threatening diseases, including orphan medicines, and medicines for public health emergencies.^[1]

The legal basis is Article 14-a of Regulation (EC) No 726/2004, with details in Regulation (EC) No 507/2006.^[1]

The four criteria

• The benefit-risk balance of the medicine is positive.^[1]
• The applicant is likely to be able to provide comprehensive data after authorisation.^[1]
• The medicine fulfils an unmet medical need.^[1]
• The benefit of immediate availability is greater than the risk of additional data still being required.^[1]

Obligations, renewal and conversion

A conditional marketing authorisation is valid for one year and can be renewed annually. The holder must meet specific obligations within set timelines, such as completing ongoing or new studies. EMA publishes the conditions in the medicine's European public assessment report.^[1]

Once the obligations are met and the full data confirm a positive benefit-risk balance, it can be converted into a standard marketing authorisation, initially valid for five years and then renewable for unlimited validity. EMA can suspend or revoke it if new data show the benefits no longer outweigh the risks, or if the company does not meet its obligations.^[1]

Conditional authorisation versus exceptional circumstances

EMA can also authorise a medicine without comprehensive data under exceptional circumstances. The difference: a conditional authorisation expects the company to provide the data within an agreed timeframe, while exceptional circumstances apply when comprehensive data cannot be obtained even after authorisation, for example because the condition is very rare.^{[1, 2]}

What it means for patients in the Gulf

Why this matters in the Gulf: Saudi Arabia's SFDA runs reliance pathways that build on decisions by other regulators. Its performance target is 30 working days for the verification pathway, which needs approval and marketing by both the US FDA and the EMA, and 60 working days for the abridged pathway, which needs one of them. The manufacturer still has to apply; nothing happens automatically.^[3]

Until a medicine is registered locally, a patient in the Gulf usually reaches an FDA-approved medicine through a hospital request to the national regulator, such as the SFDA Special Access Program in Saudi Arabia or the procedure in NHRA Circular 41 of 2020 in Bahrain.^{[4, 5]}

Questions to ask the treating specialist

• Is this medicine conditionally authorised in the EU, and what studies is the company still required to complete?
• Is it also approved by the US FDA, and does the US label carry any accelerated-approval statement?
• Is it registered in our country, or will the hospital need to request it for the named patient?
• What monitoring does the label require, and can it be done here?

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.

We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.

Sources for these answers: ^{[1, 2, 3]}

Related

• EU exceptional circumstances
• EMA PRIME scheme
• All access pathways
• US expanded access (compassionate use)
• Named-patient access, explained
• Answers to common access questions

This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.